title: Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
abstract: OBJECTIVE
  To assess the impact of switching to tenofovir disoproxil fumarate + emtricitabine on lipid parameters.
  
  
  METHODS
  HIV-infected patients with plasma viral load <400 copies/mL, fasted triglycerides from 2.3 to 11.4 mmol/L and/or fasted low-density lipoprotein (LDL)-cholesterol >4.1 mmol/L were randomized to switch the nucleoside reverse transcriptase inhibitor (NRTI) backbone to fixed-dose combination tenofovir disoproxil fumarate + emtricitabine or to maintain the baseline antiretroviral regimen (the control group). The study has been registered with ClinicalTrials.gov under the identifier NCT00323492.
  
  
  RESULTS
  Ninety-one patients were included in the intent-to-treat (ITT) analysis with triglycerides 2.4 mmol/L and LDL-cholesterol 4.0 mmol/L (median values). At week 12, the median changes from baseline of triglycerides were -0.5 mmol/L (-25%; n = 46) and -0.1 mmol/L (-6%; n = 45) in the tenofovir disoproxil fumarate + emtricitabine and control groups, respectively, indicating a difference of -0.4 mmol/L (P = 0.034) [95% confidence interval (CI): -0.9 to -0.0]. Similarly for LDL-cholesterol, changes of -0.4 mmol/L (-9%) and -0.1 mmol/L (-1%) were observed in the tenofovir disoproxil fumarate + emtricitabine and control groups, respectively, indicating a difference of -0.4 mmol/L (P = 0.031) [95% CI: -0.7 to -0.0]. The proportion of patients with LDL-cholesterol >4.1 mmol/L decreased from 48% at baseline to 26% at week 12 in the tenofovir disoproxil fumarate + emtricitabine group versus no change in the control group. No virological failure was observed during the study.
  
  
  CONCLUSIONS
  Switching to tenofovir disoproxil fumarate + emtricitabine in dyslipidaemic HIV-infected patients improves triglycerides and LDL-cholesterol.
authors.affiliation: Department of Infectious Diseases, AP-HP, Pitié-Salpêtrière Hospital, Paris, France. marc-antoine.valantin@psl.ap-hop-paris.fr
authors.forename: M A
authors.initials: MA
authors.lastname: Valantin
authors.forename: R
authors.initials: R
authors.lastname: Bittar
authors.forename: P
authors.initials: P
authors.lastname: de Truchis
authors.forename: D
authors.initials: D
authors.lastname: Bollens
authors.forename: L
authors.initials: L
authors.lastname: Slama
authors.forename: P
authors.initials: P
authors.lastname: Giral
authors.forename: D
authors.initials: D
authors.lastname: Bonnefont-Rousselot
authors.forename: P
authors.initials: P
authors.lastname: Pétour
authors.forename: C
authors.initials: C
authors.lastname: Aubron-Olivier
authors.forename: D
authors.initials: D
authors.lastname: Costagliola
authors.forename: C
authors.initials: C
authors.lastname: Katlama
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068679:Emtricitabine; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009705:Nucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D063065:Organophosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D000068698:Tenofovir; D014280:Triglycerides / Q000097:blood*
chemical_list: D019380:Anti-HIV Agents; D008078:Cholesterol, LDL; D009705:Nucleosides; D063065:Organophosphonates; D014280:Triglycerides; D003841:Deoxycytidine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine